Page last updated: 2024-08-05 14:47:26
drug metabolite
null
ChEBI ID: 49103
Members (95)
| Member | Definition | Class |
|---|---|---|
| 1-(3-chlorophenyl)piperazine | A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone. | 1-(3-chlorophenyl)piperazine |
| 1-hydroxymethylmidazolam | An imidazobenzodiazepine that is midazolam in which one of the hydrogens of the methyl group is substituted by a hydroxy group. It is the major metabolite of the anesthetic, midazolam. | 1-hydroxymidazolam |
| 1-hydroxymethylmidazolam glucuronide | A beta-D-glucosiduronic acid that is beta-D-glucuronic acid in which the anomeric hydroxyl hydrogen has been replaced by a 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepin-4-yl group. It is the glucuronidated conjugate of the midazolam metabolite, 1-hydroxymidazolam. | 1-hydroxymidazolam beta-D-glucuronide |
| 1,2,4-triazole-3-carboxamide | A member of the class of triazoles that is 1H-1,2,4-triazole substituted by an aminocarbonyl group at position 3. It is the major catabolite and aglycon of ribavirin. | 1,2,4-triazole-3-carboxamide |
| 12-hydroxynevirapine | A dipyridodiazepine that is nevirapine in which one of the hydrogens of the methyl group has been substituted by a hydroxy group. It is a metabolite of the anti-HIV drug, nevirapine. | 12-hydroxynevirapine |
| 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile | A nitrile that is pentanenitrile substituted by a 3,4-dimethoxyphenyl group at position 2, a methylamino group at position 4 and an isopropyl group at position 2. It is a metabolite of the drug verapamil. | D617 |
| 2,3,4-trihydroxbenzophenone | A benzenetriol that is benzophenone in which one of the phenyl groups is substituted by hydroxy groups at positions 2, 3, and 4. It is a redox mediator. | 2,3,4-trihydroxbenzophenone |
| 2,6-xylidine | A primary arylamine that is aniline in which the hydrogens at the 2- and 6-positions are replaced by methyl groups. It is used in the production of some anasthetics and other chemicals. It is a drug metabolite of lidocaine (local anasthetic). | 2,6-dimethylaniline |
| 3-chlorobenzoic acid | A monochlorobenzoic acid carrying a chloro substituent at position 3. | 3-chlorobenzoic acid |
| 3-hydroxymethylantipyrine | A pyrazolone that is antipyrine in which one of the hydrogens of the 5-methyl group is substituted by a hydroxymethyl group. It is a metabolite of the analgesic drug, antipyrene. | 3-hydroxymethylantipyrine |
| 3,4-dihydroxymandelic acid | A catechol that is the 3,4-dihydroxy derivative of mandelic acid; a metabolite of L-dopa. | 3,4-dihydroxymandelic acid |
| 4-formylaminoantipyrine | A pyrazolone that is 1,2-dihydro-3H-pyrazol-3-one substituted by a formaylamino group at position 4, methyl groups at positions 1 and 5 and a phenyl group at position 2. It is a metabolite of aminophenazone. | 4-formylaminoantipyrine |
| 4-hydroxymidazolam | An imidazobenzodiazepine that is midazolam which is substituted by a hydroxy group at position 4. It is the minor hydroxylated metabolite of the anesthetic, midazolam. | 4-hydroxymidazolam |
| 4-trifluoromethylphenol | A member of the class of (trifluoromethyl)benzenes that is p-cresol in which the methyl group is perfluorinated. It is a metabolite of the drug fluoxetine. | 4-(trifluoromethyl)phenol |
| 4'-hydroxydiclofenac | A monocarboxylic acid that is the 4'-hydroxylated metabolite of diclofenac. | 4'-hydroxydiclofenac |
| 5-fluorouridine 5'-phosphate | A pyrimidine ribonucleoside 5'-monophosphate having 5-fluorouracil as the pyrimidine component. | 5-fluorouridine 5'-monophosphate |
| 5-hydroxydiclofenac | A monocarboxylic acid that is the 5-hydroxylated metabolite of diclofenac. | 5-hydroxydiclofenac |
| 5-hydroxymethylomeprazole | A sulfoxide that is omeprazole in which one of the methyl hydrogens at position 5 on the pyridine ring is substituted by a hydroxy group. | 5'-hydroxyomeprazole |
| 6-methoxy-2-naphthylacetic acid | A monocarboxylic acid consisting of 2-naphthylacetic acid having a methoxy substituent at the 6-position. The active metabolite of the prodrug nabumetone. | (6-methoxy-2-naphthyl)acetic acid |
| acetaminophen glucuronide | A beta-D-glucosiduronic acid that is the O-glucuronide of paracetamol (acetaminophen). | acetaminophen O-beta-D-glucosiduronic acid |
| acetaminophen mercapturate | An S-substituted N-acetyl-L-cysteine in which the S-substitutuent is specified as 5-acetamido-2-hydroxyphenyl. | S-(5-acetamido-2-hydroxyphenyl)-N-acetyl-L-cysteine |
| acetaminophen sulfate ester | An aryl sulfate that is paracetamol in which the hydroxy group has been replaced by a sulfooxy group. | paracetamol sulfate |
| acetylhydrazine | A carbohydrazide that is hydrazine in which one of the hydrogens is replaced by an acetyl group. | acetohydrazide; acetohydrazonic acid |
| act-132577 | A member of the class of sulfamides in which one of the amino groups of sulfonamide is substituted by a 5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl group. An active metabolite of macitentan (obtained by oxidative depropylation), an orphan drug used for the treatment of pulmonary arterial hypertension. | ACT-132577 |
| adefovir | A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection. | adefovir |
| adriamycinol | A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties. | doxorubicinol |
| ampyrone | A pyrazolone, a member of the class of pyrazoles that is antipyrine substituted at C-4 by an amino group. It is a metabolite of aminopyrine and of metamizole. | 4-aminoantipyrine |
| aripiprazole | An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders. | aripiprazole |
| azauridine | 6-azauridine | |
| bay 60-4552 | A member of the class of pyrazolopyridines that is 1H-pyrazolo[3,4-b]pyridine which is substituted by a 2-fluorobenzyl and 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl groups at positions 1 and 3, respectively. It is an active metabolite of riociguat and a soluble guanylate cyclase stimulator developed by Bayer for the treatment of erectile dysfunction and heart failure. | nelociguat |
| bay-s 9435 | An organosulfonic acid that is ciprofloxacin carrying a sulfo group at position 4 of the piperazine ring. It is a metabolite of ciprofloxacin. | sulfociprofloxacin |
| brivanib | A secondary alcohol resulting from the hydrolysis of the carboxylic ester group of brivanib alaninate. It is a dual VEGFR-2/FGFR-1 kinase inhibitor whose alanine prodrug, brivanib alaninate is currently under development as an oral agent for the treatment of cancer. | (2R)-1-[[4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methyl-6-pyrrolo[2,1-f][1,2,4]triazinyl]oxy]-2-propanol; brivanib |
| carbamazepine epoxide | An epoxide and metabolite of carbamazepine. | carbamazepine-10,11-epoxide |
| carboxyibuprofen | A dicarboxylic acid that is ibuprofen in which one of the methyl groups in the isobutyl portion has been converted to the corresponding carboxylic acid. | carboxyibuprofen |
| clopidogrel carboxylic acid | A thienopyridine that is 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-ylacetic acid substituted by a 2-chlorophenyl group at position 2. It is a metabolite of the drug clopidogrel. | clopidogrel carboxylic acid |
| cyclosporine metabolite m17 | A cyclosporin A derivative that is cyclosporin A in which residue 1 [(2S,3R,4R,6E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid] has undergone allylic oxidation to give the corresponding primary allylic alcohol. It specifically inhibits growth of renal cells in culture. | cyclosporin A metabolite M17 |
| desloratadine | Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness. | desloratadine |
| desvenlafaxine | A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine. | O-desmethylvenlafaxine |
| didesethylflurazepam | A primary amino compound resulting from the dealkylation of both ethyl groups of the anti-insomnia drug flurazepam. It is the major metabolite of flurazepam. | didesethylflurazepam |
| ethisterone | A 17beta-hydroxy steroid that is testosterone in which the 17beta hydrogen is replaced by an ethynyl group. Ethisterone was the first orally active progestin and is a metabolite of danazol. | ethisterone |
| fenofibric acid | A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate. | fenofibric acid |
| glycinexylidide | A amino acid amide with 2,6-dimethylaniline and glycine components; an active metabolite of lidocaine, formed by oxidative deethylation. Used as an indicator of hepatic function. | glycinexylidide |
| GS-441524 | A C-nucleoside analog that is (2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile substituted by a 4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl group at position 2. It is the active metabolite of remdesivir and exhibits a broad range of inhibitory activity against various RNA viruses including HCV, parainfluenza and SARS-CoV. | GS-441524 |
| GS-443902 | An organic triphosphate that is GS-441524 in which the 5'-hydroxy group has been replaced by a triphosphate group. It is the active metabolite of remdesivir. | GS-443902 |
| hexafluoroisopropanol | An organofluorine compound formed by substitution of all the methyl protons in propan-2-ol by fluorine. It is a metabolite of inhalation anesthetic sevoflurane. | 1,1,1,3,3,3-hexafluoropropan-2-ol |
| hydroxyibuprofen | A hydroxy monocarboxylic acid that is ibuprofen in which the methine proton on the isobutyl group has been replaced by a hydroxy group. | 2-hydroxyibuprofen |
| hydroxyindoleacetic acid | A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5. | (5-hydroxyindol-3-yl)acetic acid |
| imidaprilat | A member of the class of imidazolidines that is imidapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of imidapril used to treat hypertension. | imidaprilat |
| indomethacin | A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis. | indometacin |
| INDY | A member of the class of benzothiazoles that is 2,3-dihydro-1,3-benzothiazole substituted by 2-oxopropylidene, ethyl, and hydroxy groups at positions 2, 3 and 5, respectively. It is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B (IC50 of 0.24 muM and 0.23 muM, respectively). | INDY |
| ixazomib | A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of [(1R)-1-amino-3-methylbutyl]boronic acid. The active metabolite of ixazomib citrate, it is used in combination therapy for treatment of multiple myeloma. | ixazomib |
| l 154819 | A polyketide obtained by hydrolysis of the pyranone ring of lovastatin. | mevinolinic acid |
| monoethylglycinexylidide | Amino acid amide formed from 2,6-dimethylaniline and N-ethylglycine components; an active metabolite of lidocaine, formed by oxidative deethylation. Used as an indicator of hepatic function. | monoethylglycinexylidide |
| monomethyl fumarate | A dicarboxylic acid monoester resulting from the formal condensation of one of the carboxy groups of fumaric acid with methanol. Is is a metabolite of dimethyl fumarate and used for the the treatment of patients with relapsing multiple sclerosis (MS). It also induces the NFE2L2 (Nrf2) transcription factor by binding to KEAP1. | monomethyl fumarate |
| mre 269 | A member of the class of pyrazines that is {4-[(propan-2-yl)(pyrazin-2-yl)amino]butoxy}acetic acid carrying two additional phenyl substituents at positions 5 and 6 on the pyrazine ring. The active metabolite of selexipag, an orphan drug used for the treatment of pulmonary arterial hypertension. | ACT-333679 |
| n-acetylaminoantipyrine | A member of the class of pyrazoles that is antipyrine substituted by an acetylamino group at position 4. It is a drug metabolite of metamizole. | 4-acetamidoantipyrine |
| n-demethylloperamide | A monocarboxylic acid amide that is the methylamide of 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylbutanoic acid. | desmethyl loperamide |
| n-desmethylvenlafaxine | A monomethoxybenzene that is the N-desmethyl derivative of venlafaxine. | N-desmethylvenlafaxine |
| n-methylthiourea | A member of the class of thioureas that is thiourea in which one of the hydrogens is replaced by a methyl group. | N-methylthiourea |
| n,o-didesmethylvenlafaxine | A secondary amino compound that is N-methylethanamine substituted by a 1-hydroxycyclohexyl and a 4-hydroxyphenyl group at position 1. It is a metabolite of the drug venlafaxine. | N,O-didesmethylvenlafaxine |
| n(4)-acetylsulfamethoxazole | A sulfonamide compound having a 4-acetamidophenyl group attached to the sulfur atom and a 1,2-oxazol-3-yl group attached to the nitrogen atom. | N-acetylsulfamethoxazole |
| n(4)-hydroxycytidine | A nucleoside analogue that is cytidine which carries a hydroxy group at the N(4)-positon. It has broad-spectrum antiviral activity against influenza, SARS-CoV , SARS-CoV-2 and MERS-CoV. | N(4)-hydroxycytidine |
| nitrazepam | A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome). | nitrazepam |
| noramidopyrine | A member of the class of pyrazoles that is antipyrine substituted at C-4 by a methylamino group. It is a metabolite of aminopyrine and of metamizole. | 4-(methylamino)antipyrine |
| norfentanyl | A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of 4-(N'-phenyl)piperidin-4-amine with propanoic acid. A major metabolite of fentanyl. | norfentanyl |
| nortilidine | An ethyl 2-(methylamino)-1-phenylcyclohex-3-ene-1-carboxylate that is ent-dextilidine in which one of the methyl groups attached to the nitrogen is replaced by hydrogen. ent-Dextilidine is metabolised to (1R,2S)-nortilidine by the liver. | (1R,2S)-nortilidine |
| nortriptyline | An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline. | nortriptyline |
| oxidopamine | A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease). | oxidopamine |
| oxociprofloxacin | 3-oxociprofloxacin | |
| oxyphenbutazone | A metabolite of phenylbutazone obtained by hydroxylation at position 4 of one of the phenyl rings. Commonly used (as its hydrate) to treat pain, swelling and stiffness associated with arthritis and gout, it was withdrawn from the market 1984 following association with blood dyscrasis and Stevens-Johnson syndrome. | oxyphenbutazone |
| oxypurinol | A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6. | alloxanthine |
| perindoprilat | A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril. | perindoprilat |
| PF-00835231 | A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity. | PF-00835231 |
| phenetidine | An aromatic ether that is aniline in which the hydrogen at position 4 is replaced by an ethoxy group. It is a hydrolysis metabolite of phenacetin. | 4-ethoxyaniline |
| prednisolone | A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone. | prednisolone |
| procainamide 4-hydroxylamine | A benzamide obtained via formal condensation of 4-hydroxylaminobenzoic acid and 2-(diethylamino)ethylamine; a metabolite in liver microsomes. | procainamide 4-hydroxylamine |
| proglumide | A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs. | N(2)-benzoyl-N,N-dipropyl-alpha-glutamine; proglumide |
| psilocin | A tryptamine alkaloid that is N,N-dimethyltryptamine carrying an additional hydroxy substituent at position 4. A hallucinogenic alkaloid isolated in trace amounts from Psilocybe mushrooms (also known as Teonanacatl or "magic mushrooms"). | psilocin |
| pyrazinoic acid | The parent compound of the class of pyrazinecarboxylic acids, that is pyrazine bearing a single carboxy substituent. The active metabolite of the antitubercular drug pyrazinamide. | pyrazine-2-carboxylic acid |
| pyridine n-oxide | The pyridine N-oxide derived from the parent pyridine. It is a drug metabolite of the antihypertensive agent pinacidil. | pyridine N-oxide |
| ramiprilat | A dipeptide that is the active metabolite of ramipril. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. | ramiprilat |
| ribavirin 5'-diphosphate | A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a phosphonooxy group. It is the active metabolite of the antiviral agent ribavirin. | ribavirin 5'-monophosphate |
| ribavirin 5'-diphosphate | A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a diphosphate group. It is the metabolite of the antiviral agent ribavirin. | ribavirin 5'-diphosphate |
| ribavirin 5'-triphosphate | A 1-ribosyltriazole that is ribavirin in which the hydroxy group at the 5'-position is replaced by a triphosphate group. It is the active metabolite of the antiviral agent ribavirin. | ribavirin 5'-triphosphate |
| ritalinic acid | A monocarboxylic acid that is phenylacetic acid substituted by a piperidin-2-yl group at position 2. It is a metabolite of the drug methylphenidate. | ritalinic acid |
| sn 38 | A member of the class of pyranoindolizinoquinolines that is (4S)-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-dione bearing two additional ethyl substituents at positions 4 and 11 as well as two additional hydroxy substituents at positions 4 and 9. It is the active metabolite of irinotecan and is ~1000 times more active than irinotecan itself. | SN-38 |
| spiraprilat | An azaspiro compound that is spirapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid group. It is the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor spirapril. | spiraprilat |
| tedizolid | A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis. | tedizolid |
| tenofovir | A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. | tenofovir (anhydrous) |
| teriflunomide | An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis. | teriflunomide |
| theophylline | A dimethylxanthine having the two methyl groups located at positions 1 and 3. It is structurally similar to caffeine and is found in green and black tea. | theophylline |
| trandolaprilat | A heterobicyclic compound that is trandolapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of the prodrug trandolapril. | trandolaprilat |
| uridine | A ribonucleoside composed of a molecule of uracil attached to a ribofuranose moiety via a beta-N(1)-glycosidic bond. | uridine |
| wr 1065 | An alkanethiol that is the N-3-aminopropyl derivative of cysteamine. Used as the S-phosphorylated prodrug, amifostine, for cytoprotection in cancer chemotherapy and radiotherapy. | WR-1065 |
| zofenoprilate | A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-2-methyl-3-sulfanylpropanoyl group. The active metabolite of zofenopril. | zofenoprilat |
Research
Studies (127,355)
| Timeframe | Studies, Drugs with This Role(%) | All Drugs % |
|---|---|---|
| pre-1990 | 55,828 (43.84) | 18.7374 |
| 1990's | 23,633 (18.56) | 18.2507 |
| 2000's | 21,073 (16.55) | 29.6817 |
| 2010's | 20,761 (16.30) | 24.3611 |
| 2020's | 6,060 (4.76) | 2.80 |
Study Types
| Publication Type | Studies, Drugs with this Role (%) | All Drugs (%) |
|---|---|---|
| Trials | 10,563 (7.72%) | 5.53% |
| Reviews | 7,050 (5.15%) | 6.00% |
| Case Studies | 16,128 (11.79%) | 4.05% |
| Observational | 348 (0.25%) | 0.25% |
| Other | 102,702 (75.08%) | 84.16% |
Protein Targets (1,068)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 29.1056 | 1 | 3 |
| 67.9K protein | Vaccinia virus | Potency | 8.9952 | 2 | 4 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 29.2347 | 2 | 8 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 15.0890 | 1 | 1 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 2 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 20.5523 | 1 | 2 |
| apical membrane antigen 1, AMA1 | Plasmodium falciparum 3D7 | Potency | 26.2000 | 1 | 2 |
| AR protein | Homo sapiens (human) | Potency | 10.4137 | 12 | 81 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 38.1125 | 2 | 7 |
| arylsulfatase A | Homo sapiens (human) | Potency | 35.8704 | 1 | 2 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 18.8979 | 3 | 4 |
| Ataxin-2 | Homo sapiens (human) | Potency | 40.1250 | 2 | 5 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 0.7569 | 1 | 1 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 46.1941 | 1 | 4 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 14.6892 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 39.6598 | 1 | 5 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 3.7578 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 3.7578 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 21.0201 | 2 | 7 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 19.3413 | 2 | 5 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 20.8114 | 1 | 2 |
| Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 67.4022 | 2 | 2 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 17.4124 | 2 | 6 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 1 | 2 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 3.5481 | 1 | 1 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 40.6765 | 1 | 4 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 58.8533 | 3 | 9 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 19.7646 | 1 | 5 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 34.8036 | 1 | 5 |
| chaperonin-containing TCP-1 beta subunit homolog | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 53.7095 | 2 | 9 |
| core-binding factor subunit beta isoform 2 | Homo sapiens (human) | Potency | 19.4998 | 3 | 3 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 12.7175 | 1 | 2 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 27.3935 | 1 | 4 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 16.0967 | 1 | 7 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 12.8847 | 1 | 7 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 11.7116 | 1 | 6 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.0252 | 2 | 8 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 14.3158 | 2 | 11 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 10.6894 | 1 | 8 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 7.9899 | 3 | 3 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 23.2809 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 8.9125 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 48.0952 | 1 | 6 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 10.4689 | 1 | 3 |
| dopamine D1 receptor | Homo sapiens (human) | Potency | 2.5929 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 8.1820 | 1 | 2 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 19.7958 | 12 | 66 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 26.4971 | 3 | 13 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 32.9064 | 6 | 49 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 16.1227 | 1 | 15 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 9.7561 | 4 | 23 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 23.8213 | 3 | 7 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 21.7896 | 1 | 2 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 12.2086 | 1 | 7 |
| G | Vesicular stomatitis virus | Potency | 16.0967 | 1 | 7 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.0252 | 1 | 4 |
| geminin | Homo sapiens (human) | Potency | 11.3903 | 2 | 20 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 22.9138 | 2 | 16 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 6.7946 | 1 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 3.8990 | 2 | 3 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 0.6310 | 1 | 1 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 4.5956 | 4 | 22 |
| Glutamate receptor 1 | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 1 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 11.5342 | 2 | 5 |
| Glutamate receptor 3 | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 1 |
| Glutamate receptor 4 | Rattus norvegicus (Norway rat) | Potency | 0.5623 | 1 | 1 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 6.5131 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 12.9630 | 2 | 5 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 35.2147 | 1 | 3 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 32.7708 | 2 | 7 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 23.9777 | 2 | 20 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 21.4054 | 1 | 4 |
| histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 25.1566 | 2 | 2 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 63.6616 | 2 | 8 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 16.0967 | 1 | 7 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 30.3001 | 1 | 2 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 15.5348 | 2 | 2 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 30.8572 | 1 | 4 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 6.4454 | 2 | 8 |
| IDH1 | Homo sapiens (human) | Potency | 13.9540 | 1 | 3 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 6.5131 | 1 | 1 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 16.0967 | 1 | 14 |
| Inositol monophosphatase 1 | Rattus norvegicus (Norway rat) | Potency | 4.2788 | 1 | 5 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 16.2710 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 16.2710 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 11.3941 | 3 | 20 |
| interleukin 8 | Homo sapiens (human) | Potency | 66.8242 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 7.2386 | 2 | 9 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 0.7943 | 1 | 1 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 43.9333 | 2 | 5 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 1.7783 | 2 | 2 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 13.7369 | 1 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 15.7176 | 2 | 4 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 9.4346 | 2 | 4 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 1.7783 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 5.7788 | 1 | 3 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 5.6234 | 2 | 2 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 7.5506 | 1 | 2 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 58.0479 | 1 | 1 |
| Nrf2 | Homo sapiens (human) | Potency | 8.5003 | 2 | 2 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 42.6137 | 3 | 17 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 11.0768 | 2 | 5 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 34.4844 | 1 | 6 |
| Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 17.2507 | 1 | 3 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 4.7484 | 2 | 5 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 9.5056 | 1 | 2 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 35.0235 | 3 | 19 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 17.7828 | 1 | 1 |
| Parkin | Homo sapiens (human) | Potency | 20.5962 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 20.6898 | 1 | 5 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 63.7414 | 1 | 2 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 15.5831 | 5 | 15 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 20.0916 | 5 | 17 |
| phosphoglycerate kinase | Trypanosoma brucei brucei TREU927 | Potency | 9.9621 | 2 | 2 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 61.2530 | 1 | 6 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 4.1426 | 1 | 3 |
| polyprotein | Zika virus | Potency | 12.2086 | 1 | 7 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 18.8541 | 1 | 4 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 6.1162 | 1 | 3 |
| PPM1D protein | Homo sapiens (human) | Potency | 9.5973 | 1 | 8 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 33.2065 | 2 | 11 |
| progesterone receptor | Homo sapiens (human) | Potency | 23.1492 | 3 | 17 |
| Rap guanine nucleotide exchange factor 3 | Homo sapiens (human) | Potency | 112.9460 | 2 | 2 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 18.2466 | 2 | 17 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 23.5557 | 1 | 3 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 21.1923 | 1 | 1 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 33.9430 | 3 | 29 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 20.1134 | 4 | 23 |
| runt-related transcription factor 1 isoform AML1b | Homo sapiens (human) | Potency | 19.4998 | 3 | 3 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 20.1219 | 4 | 5 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 23.7781 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 13.0705 | 2 | 9 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 13.0705 | 2 | 9 |
| Smad3 | Homo sapiens (human) | Potency | 13.8890 | 1 | 3 |
| snurportin-1 | Homo sapiens (human) | Potency | 6.5131 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 22.4355 | 2 | 7 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 2.4068 | 1 | 2 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 14.9936 | 1 | 4 |
| TDP1 protein | Homo sapiens (human) | Potency | 15.3721 | 2 | 26 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 34.9290 | 1 | 3 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 25.0382 | 3 | 8 |
| Thrombopoietin | Homo sapiens (human) | Potency | 12.5893 | 2 | 2 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 26.6038 | 3 | 27 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 27.9230 | 3 | 5 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 26.3219 | 5 | 14 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 8.3409 | 1 | 3 |
| tyrosine-protein kinase Yes | Homo sapiens (human) | Potency | 1.7291 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 4.1426 | 1 | 3 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 4.1426 | 1 | 3 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 26.8546 | 2 | 6 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 23.5226 | 2 | 10 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 13.0632 | 5 | 17 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 36.5084 | 5 | 11 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 14.2771 | 1 | 4 |
| Vpr | Human immunodeficiency virus 1 | Potency | 12.5893 | 1 | 1 |
| WRN | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | Ki | 0.0220 | 1 | 1 |
| 3',5'-cyclic-AMP phosphodiesterase | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | IC50 | 0.6920 | 3 | 3 |
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 4.7883 | 17 | 18 |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | Ki | 0.2352 | 7 | 7 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | IC50 | 1.0190 | 2 | 2 |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | Ki | 0.2931 | 4 | 4 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | Ki | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | Ki | 0.0250 | 1 | 1 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | IC50 | 0.7965 | 4 | 5 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | IC50 | 5.0850 | 2 | 2 |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | Ki | 0.0280 | 29 | 31 |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 0.1338 | 8 | 9 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | IC50 | 0.0600 | 2 | 3 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | Ki | 0.0243 | 9 | 10 |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | Ki | 0.0400 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | IC50 | 0.6990 | 5 | 6 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.0484 | 14 | 16 |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | Ki | 0.0447 | 3 | 3 |
| 5-hydroxytryptamine receptor 3A | Cavia porcellus (domestic guinea pig) | IC50 | 630.0000 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 0.2084 | 2 | 3 |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 0.2084 | 2 | 3 |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 0.2084 | 2 | 3 |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 0.2084 | 2 | 3 |
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 0.2084 | 2 | 3 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | IC50 | 0.0230 | 1 | 2 |
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 0.0121 | 1 | 2 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 5A | Mus musculus (house mouse) | Ki | 8.7000 | 2 | 2 |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | IC50 | 1.3625 | 1 | 2 |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 0.6469 | 10 | 11 |
| 5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 0.0655 | 10 | 10 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | IC50 | 0.1700 | 1 | 1 |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | Ki | 0.2207 | 2 | 2 |
| Adenosine deaminase | Bos taurus (cattle) | Ki | 800.0000 | 1 | 1 |
| Adenosine receptor A1 | Bos taurus (cattle) | IC50 | 1,006,650,005.0433 | 3 | 3 |
| Adenosine receptor A1 | Homo sapiens (human) | IC50 | 17.1040 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | IC50 | 67.3333 | 3 | 3 |
| Adenosine receptor A1 | Bos taurus (cattle) | Ki | 4.1143 | 7 | 7 |
| Adenosine receptor A1 | Cavia porcellus (domestic guinea pig) | Ki | 21.3333 | 6 | 6 |
| Adenosine receptor A1 | Gallus gallus (chicken) | Ki | 6.0000 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | Ki | 6.6399 | 18 | 18 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Ki | 9.2781 | 31 | 37 |
| Adenosine receptor A2a | Homo sapiens (human) | IC50 | 12.0070 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | IC50 | 164.0000 | 1 | 1 |
| Adenosine receptor A2a | Cavia porcellus (domestic guinea pig) | Ki | 14.0000 | 2 | 2 |
| Adenosine receptor A2a | Homo sapiens (human) | Ki | 8.5486 | 27 | 27 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ki | 15.9652 | 24 | 31 |
| Adenosine receptor A2b | Homo sapiens (human) | Ki | 10.1426 | 19 | 19 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | Ki | 15.3896 | 18 | 24 |
| Adenosine receptor A3 | Homo sapiens (human) | Ki | 54.8657 | 20 | 20 |
| Adenosine receptor A3 | Rattus norvegicus (Norway rat) | Ki | 45.4056 | 8 | 9 |
| Albumin | Homo sapiens (human) | Ki | 15,135,600,000.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Bos taurus (cattle) | IC50 | 5.0000 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | IC50 | 0.5596 | 1 | 2 |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | Ki | 0.5551 | 1 | 2 |
| Aldo-keto reductase family 1 member C1 | Homo sapiens (human) | IC50 | 108.6667 | 3 | 3 |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | IC50 | 48.2567 | 6 | 6 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | IC50 | 3.0988 | 8 | 8 |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | Ki | 1.1850 | 2 | 2 |
| Aldo-keto reductase family 1 member C4 | Homo sapiens (human) | IC50 | 77.0000 | 2 | 2 |
| Alkaline phosphatase, tissue-nonspecific isozyme | Homo sapiens (human) | IC50 | 52.5000 | 2 | 2 |
| Alkaline phosphatase, tissue-nonspecific isozyme | Homo sapiens (human) | Ki | 82.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | IC50 | 0.1700 | 3 | 3 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0000 | 1 | 1 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 0.0253 | 3 | 3 |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0689 | 4 | 4 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 0.1465 | 2 | 2 |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0689 | 4 | 4 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | IC50 | 0.2730 | 1 | 1 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 0.0955 | 2 | 2 |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | Ki | 0.0689 | 4 | 4 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | IC50 | 0.3660 | 2 | 2 |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | Ki | 0.1380 | 2 | 2 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | IC50 | 0.7467 | 2 | 3 |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | Ki | 0.3433 | 2 | 3 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | IC50 | 0.1015 | 2 | 2 |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | Ki | 0.0234 | 3 | 3 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | IC50 | 8.7000 | 1 | 1 |
| Amine oxidase [flavin-containing] A | Homo sapiens (human) | Ki | 2.0000 | 1 | 1 |
| Amine oxidase [flavin-containing] B | Homo sapiens (human) | IC50 | 5.7000 | 1 | 1 |
| Androgen receptor | Homo sapiens (human) | IC50 | 18.0000 | 2 | 2 |
| Androgen receptor | Rattus norvegicus (Norway rat) | IC50 | 21.3624 | 2 | 2 |
| Androgen receptor | Homo sapiens (human) | Ki | 2.6807 | 3 | 3 |
| Androgen receptor | Rattus norvegicus (Norway rat) | Ki | 0.0440 | 1 | 1 |
| Angiotensin-converting enzyme | Rattus norvegicus (Norway rat) | IC50 | 0.0036 | 2 | 3 |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | Ki | 0.0004 | 1 | 1 |
| Angiotensin-converting enzyme | Homo sapiens (human) | IC50 | 0.0012 | 2 | 2 |
| ATP-binding cassette sub-family C member 3 | Homo sapiens (human) | IC50 | 124.6250 | 1 | 8 |
| ATP-dependent Clp protease proteolytic subunit | Staphylococcus aureus subsp. aureus NCTC 8325 | IC50 | 5.3000 | 1 | 1 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | IC50 | 25.9450 | 3 | 4 |
| Autoinducer 2-binding periplasmic protein LuxP | Vibrio harveyi | IC50 | 4.0000 | 1 | 1 |
| Beta lactamase (plasmid) | Pseudomonas aeruginosa | IC50 | 43.5450 | 1 | 1 |
| Beta-1 adrenergic receptor | Homo sapiens (human) | IC50 | 2.0000 | 1 | 1 |
| Beta-2 adrenergic receptor | Canis lupus familiaris (dog) | IC50 | 18.0000 | 1 | 1 |
| Bifunctional epoxide hydrolase 2 | Homo sapiens (human) | IC50 | 1.0000 | 1 | 1 |
| Bile salt export pump | Homo sapiens (human) | IC50 | 113.0527 | 3 | 15 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | IC50 | 0.1760 | 1 | 1 |
| C-X-C chemokine receptor type 3 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| Calcium release-activated calcium channel protein 1 | Homo sapiens (human) | IC50 | 4.3000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Bos taurus (cattle) | IC50 | 340.4000 | 5 | 5 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Bos taurus (cattle) | IC50 | 300.5000 | 4 | 4 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 | 320.0000 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | IC50 | 1.8100 | 1 | 1 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | Ki | 2.0476 | 1 | 2 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Rattus norvegicus (Norway rat) | Ki | 0.5103 | 4 | 5 |
| Calpain-1 catalytic subunit | Homo sapiens (human) | IC50 | 0.4837 | 1 | 3 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | IC50 | 574.2500 | 4 | 4 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | IC50 | 527.7500 | 4 | 4 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4B | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | IC50 | 637.0000 | 3 | 3 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4C | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | IC50 | 637.0000 | 3 | 3 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | Ki | 530.0000 | 1 | 1 |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Rattus norvegicus (Norway rat) | Ki | 530.0000 | 1 | 1 |
| Canalicular multispecific organic anion transporter 1 | Homo sapiens (human) | IC50 | 145.7500 | 2 | 8 |
| caspase recruitment domain family, member 15 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Caspase-2 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cathepsin B | Homo sapiens (human) | IC50 | 0.8102 | 3 | 5 |
| Cathepsin D | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Cathepsin K | Homo sapiens (human) | IC50 | 0.4837 | 1 | 3 |
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 | 210.0000 | 1 | 1 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | IC50 | 300.0000 | 2 | 2 |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase B | Homo sapiens (human) | IC50 | 300.0000 | 2 | 2 |
| Chain A, Cytidine Deaminase | Escherichia coli | Ki | 800.0000 | 1 | 1 |
| Chain A, Cytosol aminopeptidase | Bos taurus (cattle) | Ki | 0.8000 | 1 | 1 |
| Chain A, Inosine-5'-monophosphate Dehydrogenase | Tritrichomonas suis | Ki | 0.0650 | 1 | 4 |
| Chain A, membrane-associated prostaglandin E synthase-2 | Macaca fascicularis (crab-eating macaque) | IC50 | 1,000.0000 | 1 | 1 |
| Chain A, Pyridoxal Kinase | Homo sapiens (human) | Ki | 50.0000 | 1 | 2 |
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | IC50 | 57.6600 | 1 | 1 |
| Chitotriosidase-1 | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 2 |
| Cholecystokinin receptor type A | Cavia porcellus (domestic guinea pig) | IC50 | 800.0000 | 1 | 1 |
| Cholecystokinin receptor type A | Rattus norvegicus (Norway rat) | IC50 | 250.0000 | 1 | 1 |
| Corticosteroid-binding globulin | Homo sapiens (human) | Ki | 0.0309 | 1 | 1 |
| Cytidine deaminase | Homo sapiens (human) | Ki | 0.0000 | 1 | 1 |
| Cytochrome c oxidase subunit 2 | Homo sapiens (human) | IC50 | 0.3400 | 2 | 2 |
| Cytochrome P450 1A2 | Homo sapiens (human) | IC50 | 40.0000 | 1 | 1 |
| Cytochrome P450 2C19 | Homo sapiens (human) | IC50 | 21.5000 | 2 | 2 |
| Cytochrome P450 2C8 | Homo sapiens (human) | Ki | 49.9000 | 1 | 1 |
| Cytochrome P450 2C9 | Homo sapiens (human) | IC50 | 45.0000 | 2 | 2 |
| Cytochrome P450 2D1 | Rattus norvegicus (Norway rat) | IC50 | 204.0000 | 1 | 1 |
| Cytochrome P450 2D26 | Rattus norvegicus (Norway rat) | IC50 | 1.9000 | 1 | 1 |
| Cytochrome P450 2D3 | Rattus norvegicus (Norway rat) | IC50 | 14.2000 | 1 | 1 |
| Cytochrome P450 2D4 | Rattus norvegicus (Norway rat) | IC50 | 19.3000 | 1 | 1 |
| Cytochrome P450 2D6 | Homo sapiens (human) | IC50 | 16.3000 | 6 | 6 |
| Cytochrome P450 2J2 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | IC50 | 16.5535 | 7 | 8 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Ki | 8.7695 | 3 | 4 |
| Cytochrome P450 3A5 | Homo sapiens (human) | IC50 | 0.3000 | 1 | 2 |
| Cytosolic phospholipase A2 gamma | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
| D | Rattus norvegicus (Norway rat) | Ki | 0.9869 | 3 | 3 |
| D(1A) dopamine receptor | Homo sapiens (human) | IC50 | 0.5390 | 1 | 1 |
| D(1A) dopamine receptor | Homo sapiens (human) | Ki | 0.5433 | 6 | 7 |
| D(1B) dopamine receptor | Homo sapiens (human) | Ki | 1.6000 | 2 | 2 |
| D(2) dopamine receptor | Homo sapiens (human) | IC50 | 0.0158 | 4 | 5 |
| D(2) dopamine receptor | Homo sapiens (human) | Ki | 0.2797 | 35 | 36 |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.2092 | 5 | 5 |
| D(3) dopamine receptor | Homo sapiens (human) | IC50 | 1.0425 | 1 | 2 |
| D(3) dopamine receptor | Homo sapiens (human) | Ki | 0.0371 | 20 | 22 |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.0006 | 1 | 1 |
| D(4) dopamine receptor | Homo sapiens (human) | Ki | 0.1456 | 12 | 13 |
| D(4) dopamine receptor | Rattus norvegicus (Norway rat) | Ki | 0.5100 | 1 | 1 |
| Dehydrogenase/reductase SDR family member 9 | Homo sapiens (human) | IC50 | 14.0000 | 1 | 1 |
| Dihydrofolate reductase | Homo sapiens (human) | IC50 | 0.3880 | 1 | 1 |
| Dihydroorotate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | IC50 | 98.8725 | 4 | 4 |
| Dihydroorotate dehydrogenase | Schistosoma mansoni | IC50 | 50.0000 | 2 | 2 |
| Dihydroorotate dehydrogenase | Plasmodium falciparum (malaria parasite P. falciparum) | Ki | 22.6750 | 2 | 2 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | IC50 | 0.6295 | 20 | 20 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | IC50 | 0.1212 | 4 | 4 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | IC50 | 0.0172 | 6 | 6 |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | Ki | 0.9207 | 3 | 3 |
| DNA polymerase alpha catalytic subunit | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| DNA repair protein RAD52 homolog | Homo sapiens (human) | IC50 | 0.7790 | 1 | 1 |
| DNA topoisomerase 1 | Homo sapiens (human) | IC50 | 3.2500 | 2 | 2 |
| DNA topoisomerase 1 | Mus musculus (house mouse) | IC50 | 4.0000 | 1 | 1 |
| DNA-directed RNA polymerase, mitochondrial | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | IC50 | 0.2400 | 3 | 3 |
| Endochitinase B1 | Aspergillus fumigatus | IC50 | 1,000.0000 | 1 | 2 |
| Endothelin receptor type B | Homo sapiens (human) | IC50 | 0.9870 | 2 | 2 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | IC50 | 0.9870 | 1 | 1 |
| Endothelin-1 receptor | Homo sapiens (human) | IC50 | 0.0034 | 2 | 2 |
| Epidermal growth factor receptor | Homo sapiens (human) | IC50 | 5.9500 | 2 | 2 |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | IC50 | 52.0000 | 1 | 1 |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | Ki | 51.0000 | 1 | 1 |
| Equilibrative nucleoside transporter 2 | Homo sapiens (human) | IC50 | 234.0000 | 1 | 1 |
| Equilibrative nucleoside transporter 2 | Homo sapiens (human) | Ki | 242.0000 | 1 | 1 |
| Estrogen receptor | Homo sapiens (human) | IC50 | 55.0000 | 2 | 2 |
| Estrogen receptor | Homo sapiens (human) | Ki | 3.6667 | 3 | 3 |
| Estrogen receptor beta | Homo sapiens (human) | IC50 | 55.0000 | 2 | 2 |
| Estrogen receptor beta | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| Fatty acid-binding protein, intestinal | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| Fatty acid-binding protein, liver | Homo sapiens (human) | Ki | 2.1200 | 1 | 3 |
| Fatty acid-binding protein, liver | Rattus norvegicus (Norway rat) | Ki | 19.6934 | 3 | 7 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | IC50 | 0.0680 | 3 | 3 |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 BH10 | IC50 | 3.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Bos taurus (cattle) | IC50 | 0.0380 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Bos taurus (cattle) | IC50 | 0.0380 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Bos taurus (cattle) | IC50 | 0.0380 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Bos taurus (cattle) | IC50 | 0.0380 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Bos taurus (cattle) | IC50 | 0.0380 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Bos taurus (cattle) | IC50 | 0.0380 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit theta | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Gastrin/cholecystokinin type B receptor | Rattus norvegicus (Norway rat) | IC50 | 50.0000 | 1 | 1 |
| Genome polyprotein | IC50 | 215.0000 | 1 | 2 | |
| Glucocorticoid receptor | Homo sapiens (human) | IC50 | 0.0546 | 41 | 42 |
| Glucocorticoid receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0565 | 3 | 3 |
| Glucocorticoid receptor | Homo sapiens (human) | Ki | 0.0093 | 15 | 16 |
| glucose-6-phosphate 1-dehydrogenase isoform b | Homo sapiens (human) | IC50 | 80.0000 | 1 | 1 |
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | IC50 | 63.1250 | 3 | 4 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Ki | 0.0090 | 1 | 1 |
| Glyceraldehyde-3-phosphate dehydrogenase | Homo sapiens (human) | IC50 | 8.0000 | 1 | 1 |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | IC50 | 0.1125 | 1 | 2 |
| Glycine receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 0.0512 | 1 | 2 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | IC50 | 0.1125 | 1 | 2 |
| Glycine receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 0.0512 | 1 | 2 |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | IC50 | 0.1125 | 1 | 2 |
| Glycine receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 0.0512 | 1 | 2 |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | IC50 | 0.1125 | 1 | 2 |
| Glycine receptor subunit beta | Rattus norvegicus (Norway rat) | Ki | 0.0512 | 1 | 2 |
| High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7A | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | IC50 | 0.2203 | 5 | 6 |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | IC50 | 0.0000 | 1 | 2 |
| Histamine H1 receptor | Cavia porcellus (domestic guinea pig) | Ki | 0.0489 | 1 | 1 |
| Histamine H1 receptor | Homo sapiens (human) | Ki | 0.0193 | 8 | 9 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | IC50 | 7.0000 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | IC50 | 1.7165 | 1 | 2 |
| Histamine H2 receptor | Rattus norvegicus (Norway rat) | IC50 | 2,500.0000 | 1 | 1 |
| Histamine H2 receptor | Homo sapiens (human) | Ki | 1.1256 | 2 | 3 |
| Histamine H3 receptor | Homo sapiens (human) | Ki | 1.1852 | 2 | 2 |
| Hydroxycarboxylic acid receptor 2 | Homo sapiens (human) | Ki | 0.1800 | 1 | 1 |
| Indoleamine 2,3-dioxygenase 1 | Mus musculus (house mouse) | IC50 | 0.0820 | 1 | 2 |
| Interleukin-8 | Homo sapiens (human) | IC50 | 0.0500 | 1 | 1 |
| Intestinal-type alkaline phosphatase | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Janus kinase 2 (a protein tyrosine kinase) | Homo sapiens (human) | IC50 | 6.7980 | 1 | 1 |
| Lactoylglutathione lyase | Homo sapiens (human) | Ki | 22.1667 | 3 | 3 |
| Lysine-specific demethylase 4C | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
| Lysine-specific demethylase 4C | Homo sapiens (human) | Ki | 200.0000 | 1 | 1 |
| Mineralocorticoid receptor | Homo sapiens (human) | IC50 | 0.0322 | 5 | 5 |
| Mineralocorticoid receptor | Homo sapiens (human) | Ki | 0.0186 | 2 | 2 |
| Mu-type opioid receptor | Homo sapiens (human) | Ki | 0.0006 | 1 | 1 |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | IC50 | 315.0000 | 1 | 2 |
| Multidrug and toxin extrusion protein 2 | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
| Multidrug resistance-associated protein 1 | Homo sapiens (human) | IC50 | 12.3000 | 2 | 2 |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | IC50 | 117.1000 | 1 | 8 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | IC50 | 0.1745 | 1 | 2 |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 0.0420 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | IC50 | 0.2270 | 1 | 2 |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 0.0805 | 1 | 2 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | IC50 | 33.5390 | 2 | 3 |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 0.0655 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | IC50 | 0.2170 | 1 | 2 |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 0.0300 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | IC50 | 0.1595 | 1 | 2 |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 0.1150 | 1 | 2 |
| NACHT, LRR and PYD domains-containing protein 3 | Mus musculus (house mouse) | IC50 | 0.1995 | 1 | 1 |
| NAD-dependent protein deacetylase sirtuin-6 | Homo sapiens (human) | IC50 | 926.8000 | 1 | 1 |
| Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | IC50 | 0.0040 | 1 | 1 |
| Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | IC50 | 0.0040 | 1 | 1 |
| Neutrophil elastase | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Nicotinate phosphoribosyltransferase | Homo sapiens (human) | Ki | 0.0002 | 1 | 3 |
| Nitric oxide synthase, inducible | Mus musculus (house mouse) | IC50 | 24.3500 | 5 | 5 |
| Orotidine 5'-phosphate decarboxylase | Methanothermobacter thermautotrophicus str. Delta H | Ki | 349.7500 | 3 | 4 |
| Orotidine 5'-phosphate decarboxylase | Saccharomyces cerevisiae S288C | Ki | 0.0640 | 1 | 1 |
| P2X purinoceptor 4 | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| P2Y purinoceptor 12 | Rattus norvegicus (Norway rat) | IC50 | 0.9600 | 1 | 1 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | IC50 | 34.1250 | 8 | 8 |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | Ki | 35.0000 | 1 | 1 |
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | IC50 | 141.5000 | 6 | 6 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | IC50 | 2,904.0000 | 1 | 1 |
| Phosphodiesterase | Bos taurus (cattle) | IC50 | 250.3333 | 6 | 6 |
| Phosphodiesterase | Bos taurus (cattle) | Ki | 77.0000 | 1 | 1 |
| Phospholipase A-2-activating protein | Homo sapiens (human) | IC50 | 5.0000 | 1 | 1 |
| Phospholipase A2, major isoenzyme | Sus scrofa (pig) | IC50 | 1,000.0000 | 1 | 1 |
| Phosphoribosyl pyrophosphate synthase-associated protein 2 | Homo sapiens (human) | Ki | 3,000.0000 | 1 | 1 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
| Polyphenol oxidase 1 | Agaricus bisporus | IC50 | 10.5000 | 1 | 1 |
| Polyphenol oxidase 2 | Agaricus bisporus | IC50 | 2.6100 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 | 771.4000 | 5 | 5 |
| Potassium voltage-gated channel subfamily D member 3 | Homo sapiens (human) | IC50 | 5,011.8700 | 1 | 1 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 | 1,866.8339 | 10 | 11 |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 0.8793 | 3 | 3 |
| Procathepsin L | Homo sapiens (human) | IC50 | 2.6794 | 3 | 5 |
| Progesterone receptor | Homo sapiens (human) | IC50 | 6.0133 | 6 | 6 |
| Progesterone receptor | Homo sapiens (human) | Ki | 5.4286 | 7 | 7 |
| Prolyl 4-hydroxylase subunit alpha-1 | Gallus gallus (chicken) | Ki | 9.0000 | 1 | 1 |
| Prostacyclin receptor | Homo sapiens (human) | IC50 | 0.2880 | 1 | 1 |
| Prostaglandin D2 receptor | Mus musculus (house mouse) | IC50 | 10.0000 | 1 | 1 |
| Prostaglandin D2 receptor | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin D2 receptor 2 | Homo sapiens (human) | Ki | 4.0250 | 2 | 2 |
| Prostaglandin E synthase | Homo sapiens (human) | IC50 | 40.6000 | 1 | 1 |
| Prostaglandin E2 receptor EP1 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP2 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP3 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin E2 receptor EP4 subtype | Mus musculus (house mouse) | Ki | 10.0000 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | IC50 | 15.9340 | 58 | 64 |
| Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | IC50 | 0.0110 | 2 | 2 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 | 1.7024 | 76 | 93 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Ki | 7.9000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | IC50 | 12.6423 | 11 | 14 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 | 0.5461 | 7 | 7 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | IC50 | 8.4642 | 96 | 109 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 | 1.2712 | 14 | 23 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | IC50 | 73.7305 | 26 | 28 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Ki | 3.8333 | 2 | 3 |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | Ki | 9.8600 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | IC50 | 0.7764 | 6 | 9 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 | 0.5504 | 7 | 7 |
| Prostaglandin-H2 D-isomerase | Mus musculus (house mouse) | IC50 | 1.1000 | 2 | 2 |
| Protease | Human immunodeficiency virus 1 | IC50 | 10.0000 | 1 | 1 |
| Proteasome subunit alpha type-1 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha type-2 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha type-3 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha type-4 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha type-5 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha type-6 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha type-7 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit alpha-type 8 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-1 | Homo sapiens (human) | IC50 | 0.0163 | 3 | 3 |
| Proteasome subunit beta type-10 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-11 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-2 | Homo sapiens (human) | IC50 | 1.1817 | 3 | 3 |
| Proteasome subunit beta type-3 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-4 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-5 | Homo sapiens (human) | IC50 | 0.0065 | 5 | 5 |
| Proteasome subunit beta type-6 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-7 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-8 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Proteasome subunit beta type-9 | Homo sapiens (human) | IC50 | 0.0150 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | IC50 | 757.0000 | 1 | 1 |
| Protein cereblon | Homo sapiens (human) | Ki | 390.0000 | 1 | 1 |
| Protein farnesyltransferase subunit beta | Homo sapiens (human) | IC50 | 65.0000 | 1 | 1 |
| Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Homo sapiens (human) | IC50 | 65.0000 | 1 | 1 |
| Protein kinase C alpha type | Homo sapiens (human) | IC50 | 25.0000 | 1 | 1 |
| Prothrombin | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| receptor-interacting serine/threonine-protein kinase 2 isoform 1 | Homo sapiens (human) | IC50 | 6.6330 | 1 | 1 |
| Renin | Homo sapiens (human) | Ki | 2.3250 | 1 | 2 |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | IC50 | 0.0040 | 1 | 1 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | IC50 | 7.5259 | 12 | 17 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | IC50 | 20.9977 | 4 | 6 |
| Replicase polyprotein 1ab | Avian infectious bronchitis virus (strain Beaudette CK) | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Feline infectious peritonitis virus (strain 79-1146) | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Human coronavirus 229E | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Human coronavirus HKU1 (isolate N5) | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Human coronavirus NL63 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Human coronavirus OC43 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Murine hepatitis virus strain A59 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Pipistrellus bat coronavirus HKU5 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Porcine epidemic diarrhea virus CV777 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Rousettus bat coronavirus HKU9 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | Ki | 0.0009 | 1 | 12 |
| Replicase polyprotein 1ab | Tylonycteris bat coronavirus HKU4 | Ki | 0.0009 | 1 | 12 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | IC50 | 1.6900 | 6 | 6 |
| Rho-associated protein kinase 2 | Rattus norvegicus (Norway rat) | IC50 | 7.7000 | 1 | 2 |
| RNA-directed RNA polymerase | IC50 | 5.6000 | 1 | 1 | |
| Serum paraoxonase/arylesterase 1 | Homo sapiens (human) | Ki | 97.0000 | 1 | 1 |
| Sigma intracellular receptor 2 | Rattus norvegicus (Norway rat) | IC50 | 0.4900 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Cavia porcellus (domestic guinea pig) | Ki | 7.9000 | 1 | 1 |
| Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | Ki | 0.0008 | 1 | 1 |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | IC50 | 172.0790 | 3 | 3 |
| Sodium- and chloride-dependent betaine transporter | Mus musculus (house mouse) | IC50 | 170.4120 | 1 | 2 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 | 0.2000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 1 | Mus musculus (house mouse) | IC50 | 389.0225 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 | 0.2000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 2 | Mus musculus (house mouse) | IC50 | 269.5765 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 | 0.2000 | 1 | 1 |
| Sodium- and chloride-dependent GABA transporter 3 | Mus musculus (house mouse) | IC50 | 250.0945 | 1 | 2 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 | 0.2000 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | IC50 | 14.0000 | 1 | 1 |
| Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | Ki | 0.0120 | 1 | 1 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | IC50 | 2.7785 | 1 | 2 |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | Ki | 1.7563 | 2 | 3 |
| Sodium-dependent neutral amino acid transporter B(0)AT2 | Homo sapiens (human) | IC50 | 172.0000 | 1 | 1 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | IC50 | 0.7893 | 3 | 4 |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 0.4416 | 3 | 4 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | IC50 | 0.0782 | 3 | 4 |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 0.3791 | 9 | 10 |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | Ki | 0.3240 | 1 | 1 |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | IC50 | 5.8000 | 1 | 1 |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | Ki | 5.2000 | 1 | 1 |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | IC50 | 32.0000 | 1 | 1 |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | Ki | 31.0000 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | IC50 | 117.7400 | 1 | 1 |
| Solute carrier family 22 member 2 | Homo sapiens (human) | IC50 | 239.0000 | 1 | 1 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | IC50 | 15.5000 | 2 | 2 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Ki | 15.4000 | 2 | 3 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Ki | 5.9500 | 1 | 1 |
| Solute carrier family 28 member 3 | Homo sapiens (human) | IC50 | 5.4000 | 1 | 1 |
| Solute carrier family 28 member 3 | Homo sapiens (human) | Ki | 3.4000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1A3 | Rattus norvegicus (Norway rat) | Ki | 1,000.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | IC50 | 8.0000 | 2 | 2 |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | Ki | 11.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | IC50 | 41.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | Ki | 38.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | IC50 | 140.0000 | 1 | 1 |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | Ki | 130.0000 | 1 | 1 |
| Stromal interaction molecule 1 | Homo sapiens (human) | IC50 | 4.3000 | 1 | 1 |
| Substance-P receptor | Cavia porcellus (domestic guinea pig) | IC50 | 5.7000 | 1 | 1 |
| Thiopurine S-methyltransferase | Homo sapiens (human) | IC50 | 194.9840 | 1 | 1 |
| Thromboxane-A synthase | Homo sapiens (human) | IC50 | 50.0500 | 2 | 2 |
| Thyroid hormone receptor beta | Rattus norvegicus (Norway rat) | Ki | 14.0000 | 1 | 1 |
| Translocator protein | Homo sapiens (human) | IC50 | 100,000.0000 | 1 | 1 |
| Transporter | Rattus norvegicus (Norway rat) | Ki | 0.0510 | 1 | 1 |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | IC50 | 2.5000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | IC50 | 360.0000 | 1 | 1 |
| Uracil nucleotide/cysteinyl leukotriene receptor | Homo sapiens (human) | IC50 | 29.2000 | 2 | 3 |
| Uridine 5'-monophosphate synthase | Homo sapiens (human) | Ki | 280.3333 | 2 | 3 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | IC50 | 0.3800 | 1 | 1 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | Ki | 0.0600 | 1 | 1 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | IC50 | 0.0255 | 4 | 4 |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | IC50 | 0.0890 | 1 | 1 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | Ki | 0.0260 | 1 | 1 |
| Vascular endothelial growth factor receptor 2 | Mus musculus (house mouse) | Ki | 0.0280 | 1 | 1 |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
| Xanthine dehydrogenase/oxidase | Homo sapiens (human) | Ki | 0.5175 | 2 | 2 |
Activation Measurements
Other Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | K0.5 | 0.0060 | 1 | 1 |
| Adenosine deaminase | Bos taurus (cattle) | Km | 430.0000 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | Affinity constant | 10.0000 | 1 | 1 |
| Adenosine receptor A1 | Rattus norvegicus (Norway rat) | Kb | 8.7000 | 1 | 1 |
| Adenosine receptor A1 | Homo sapiens (human) | KD hydro | 2,500.0000 | 1 | 1 |
| Adenosine receptor A2a | Homo sapiens (human) | Affinity constant | 10.0000 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Kb | 13.7000 | 1 | 1 |
| Adenosine receptor A2a | Rattus norvegicus (Norway rat) | Ratio | 25.0000 | 1 | 2 |
| Adenosine receptor A2b | Homo sapiens (human) | Affinity constant | 10.0000 | 1 | 1 |
| Adenosine receptor A2b | Mus musculus (house mouse) | Kb | 16.0000 | 1 | 1 |
| Adenosine receptor A2b | Rattus norvegicus (Norway rat) | Ratio | 25.0000 | 1 | 2 |
| Adenylate cyclase type 1 | Homo sapiens (human) | Kb | 14.0000 | 1 | 1 |
| Adenylate kinase 2, mitochondrial | Homo sapiens (human) | Km | 4,500.0000 | 1 | 2 |
| Adenylate kinase isoenzyme 1 | Homo sapiens (human) | Km | 4,500.0000 | 1 | 2 |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | Km | 4.0000 | 1 | 1 |
| Carbonic anhydrase 1 | Homo sapiens (human) | Kinact | 284.0000 | 1 | 1 |
| Carbonic anhydrase 2 | Homo sapiens (human) | Kinact | 7.5000 | 1 | 1 |
| Carbonic anhydrase 5A, mitochondrial | Homo sapiens (human) | Kinact | 0.1030 | 1 | 1 |
| Carbonic anhydrase 5B, mitochondrial | Homo sapiens (human) | Kinact | 0.0980 | 1 | 1 |
| Caspase-1 | Homo sapiens (human) | ID50 | 30.0000 | 1 | 1 |
| Cholinesterase | Homo sapiens (human) | Activity | 0.0400 | 1 | 1 |
| Cytochrome P450 1A2 | Homo sapiens (human) | Km | 45.0000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | Km | 32.7000 | 1 | 1 |
| Cytochrome P450 3A4 | Homo sapiens (human) | MEC | 0.3000 | 1 | 1 |
| DNA topoisomerase 1 | Homo sapiens (human) | CC50 | 0.8000 | 1 | 1 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | Activity | 0.2760 | 1 | 1 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | Activity | 0.2760 | 1 | 1 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | Activity | 0.2760 | 1 | 1 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | Activity | 0.2760 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | Activity | 0.0024 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | ED50 | 0.0040 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | fEC50 | 0.0240 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | fIC20 | 0.0009 | 1 | 1 |
| Glucocorticoid receptor | Homo sapiens (human) | fIC30 | 0.0200 | 1 | 1 |
| Guanylate cyclase soluble subunit alpha-1 | Rattus norvegicus (Norway rat) | MEC | 0.3000 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | K0.5 | 0.0151 | 1 | 2 |
| HSP40, subfamily A [Plasmodium falciparum 3D7] | Plasmodium falciparum 3D7 | AbsAC1000_uM | 12.0000 | 1 | 1 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | AC50 | 52.0000 | 1 | 1 |
| Microphthalmia-associated transcription factor | Homo sapiens (human) | AC50 | 35.0000 | 1 | 1 |
| Phosphoribosyl pyrophosphate synthase-associated protein 2 | Homo sapiens (human) | Km | 1,500.0000 | 1 | 1 |
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | ID50 | 25.0000 | 1 | 1 |
| Progesterone receptor | Homo sapiens (human) | Activity | 5.0000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | Kinact | 3.9000 | 1 | 1 |
| Prostaglandin G/H synthase 1 | Bos taurus (cattle) | ID50 | 0.4300 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | Activity | 0.2500 | 1 | 1 |
| Prostaglandin G/H synthase 2 | Bos taurus (cattle) | ID50 | 0.4300 | 1 | 1 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | Activity | 1.6800 | 5 | 5 |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | Km | 1,112.5000 | 4 | 4 |
| Skn7p | Saccharomyces cerevisiae (brewer's yeast) | AbsAC40_uM | 0.8820 | 1 | 1 |
| Solute carrier family 22 member 1 | Homo sapiens (human) | Km | 7.7000 | 1 | 1 |
| Solute carrier family 22 member 3 | Homo sapiens (human) | Km | 49.1000 | 1 | 1 |
| Solute carrier family 22 member 6 | Homo sapiens (human) | Km | 27.8500 | 3 | 4 |
| Solute carrier family 22 member 6 | Rattus norvegicus (Norway rat) | Km | 270.0000 | 1 | 1 |
| Solute carrier family 22 member 7 | Rattus norvegicus (Norway rat) | Km | 0.3660 | 1 | 1 |
| Solute carrier family 22 member 8 | Homo sapiens (human) | Km | 995.0000 | 1 | 2 |
| Taste receptor type 2 member 38 | Homo sapiens (human) | Activity | 100.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1-6 | Homo sapiens (human) | Km | 97.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A1 | Homo sapiens (human) | Km | 24.5000 | 2 | 2 |
| UDP-glucuronosyltransferase 1A4 | Homo sapiens (human) | Km | 147.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A7 | Homo sapiens (human) | Km | 5.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 1A9 | Homo sapiens (human) | Km | 13.0000 | 1 | 1 |
| UDP-glucuronosyltransferase 2B15 | Homo sapiens (human) | Km | 186.0000 | 1 | 1 |
| Uridine-cytidine kinase 1 | Homo sapiens (human) | Km | 407.0000 | 1 | 1 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | Activity | 0.0400 | 1 | 1 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | Activity | 0.0400 | 1 | 1 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | Activity | 0.0400 | 1 | 1 |
| Vasopressin V2 receptor | Sus scrofa (pig) | Kb | 14.0000 | 1 | 1 |